肺癌,靶向治疗 z-bo 2020-09-17 353

　　Lung cancer screening

　　Dr. Chris said that the most impressive decision in 2014 was that CMS will pay for CT examinations for asymptomatic patients aged 55 to 74 who have never smoked. I believe this is a change. The regulation came into effect in January 2015 and applies to current smokers and smokers who have quit smoking within the last 15 years. Dr. Chris said that this decision will cover 8 million eligible Americans, of which 20,000 will receive timely diagnosis and treatment through early screening.

　　EGFR inhibitor

　　For lung cancer patients who are resistant to epithelial growth factor receptor (EGFR) inhibitors, the development of new drugs is another major advancement. T790 site mutation is the most common type of resistance to EGFR inhibitors. In recent years, three drugs for this mutation, Rocotinib (ClovisOncology), AZD9291 (AstraZeneca) and HM61713 (Hanmi) have achieved good development.

　　Dr. West said: "Almost 100% of patients are resistant to EGFR inhibitors, and 60% of patients have T790 mutations. Therefore, these therapies provide alternative treatment options for two-thirds of patients. Add:"

　　immune checkpoint inhibitor

　　In 2014, therapeutic antibodies that block PD-1 and PD-L1 are still the focus of research. The percentage of patients who responded to these drugs. Although small, it has significant benefits for sensitive patients due to its powerful long-acting effect

　　The second-generation ALK inhibitor targeted undifferentiated lymphoma kinase (ALK) at the recent ESMO meeting. The Phase 3 study report of the drug showed that crizotinib used to treat ALK-positive non-small cell lung cancer can prolong survival by 4 months. In April 2014, the FDA approved seritinib (ALK's second targeted drug), Alextinib, AP26113 and other second-generation ALKs. According to reports, targeted drugs will also enter phase 3 clinical trials

　　Targeted therapy

　　Dr. Kris Last year, scientists discovered more oncogenic driver genes, thereby increasing the opportunities for targeted therapy. In a lung cancer mutation study involving Dr. Chris, 10 carcinogens (KRAS, EGFR, ERBB2, BRAF, etc.) were detected in 733 tumors, and 64% of the patients had oncogenic driver genes in the test results. Patients with cancer genes were randomly divided into two groups. The median survival time of patients who received targeted therapy and who carried tumor genes but targeted therapy was 3.5 years. Dr. Chris replied: "This is 1.1 years longer than untreated patients. He said: "Multiple tests have gradually become part of the standard treatment. "